Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Stocks in this Quantisnow insightHealth Care
Historical context for ALGS
Across the 8 sessions after earlier ALGS headlines, the stock closed higher 4 times and lower 4 times, with a median move of 4.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ALGS | SPY |
|---|---|---|---|
| Jan 13, 2026 | Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer | +6.1% | -0.2% |
| Dec 12, 2025 | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +15.5% | -1.1% |
| Dec 11, 2025 | Aligos Therapeutics Presents Positive Data at HEP-DART 2025 | +1.6% | +0.2% |
| Nov 14, 2025 | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +9.7% | -0.0% |
| Nov 10, 2025 | Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025 | -2.6% | +1.6% |
| Nov 6, 2025 | Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results | -3.1% | -1.1% |
Keep researching ALGS
Quantisnow market dataNASDAQ
ALGS
Aligos Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2020
Get push alerts for ALGS
Full ALGS profile on Quantisnow Follow ALGS and get a push notification the moment its next story breaks.